Insider Trading March 9, 2026

Bankwell Director Purchases $18,078 in Stock as Company Posts Beat on Q4 Results

Carl M. Porto adds to his stake while BWFG posts EPS and revenue above expectations; shares slip in pre-market trading

By Marcus Reed BWFG
Bankwell Director Purchases $18,078 in Stock as Company Posts Beat on Q4 Results
BWFG

Carl M. Porto, a director at Bankwell Financial Group, Inc. (NASDAQ:BWFG), purchased 393 shares on March 6, 2026, at $46 per share, a transaction totaling $18,078. The trade occurred as the stock was quoted at $45.05, following a 57% gain over the prior 12 months. Separately, Bankwell reported fourth-quarter 2025 results that topped consensus on both earnings and revenue, yet the shares fell in pre-market trading. InvestingPro analysis cited a P/E of 10.56 for BWFG and noted the availability of an extended Pro Research Report covering the company and more than 1,400 U.S. equities.

Key Points

  • A Bankwell director, Carl M. Porto, purchased 393 shares at $46 each on March 6, 2026, for $18,078.
  • Bankwell beat expectations in Q4 2025 with EPS of $1.36 (vs. $1.19) and revenue of $30.32 million (vs. $28.06 million).
  • InvestingPro lists BWFG at a P/E of 10.56 and provides a Pro Research Report covering BWFG and over 1,400 U.S. stocks - sectors impacted include regional banking and financial services, as well as equity markets more broadly.

Carl M. Porto, a member of the board at Bankwell Financial Group, Inc. (NASDAQ:BWFG), executed a purchase of 393 shares of common stock on March 6, 2026. The shares were acquired at $46.00 apiece, making the total value of the transaction $18,078. At the time the report was filed, BWFG shares were trading at $45.05, after the stock delivered a 57% return over the previous year.

Following the March 6 transaction, Porto's declared direct holdings in Bankwell common stock consist of 400 shares, 534 shares, 1,200 shares, 1,455 shares and 22,398 shares. In addition to these direct positions, Porto is reported to hold 21,700 shares indirectly through a Deferred Compensation Plan and 4,303 shares indirectly through a Law Firm Pension Plan.

Market commentary included an InvestingPro assessment that assigns BWFG a price-to-earnings ratio of 10.56 at current price levels. The same research offering makes available a Pro Research Report for BWFG, alongside coverage for more than 1,400 U.S. equities, for investors seeking additional detail.

Bankwell's recent fourth-quarter 2025 financials showed an earnings-per-share result of $1.36, ahead of the $1.19 analysts had expected, representing a 14.29% earnings surprise. Revenue for the quarter was reported at $30.32 million versus consensus projections of $28.06 million, a figure that also exceeded forecasts.

Despite the company topping expectations on both EPS and revenue, the stock traded lower in pre-market sessions following the release, indicating a mixed reception from market participants. The company's quarterly results attracted attention from multiple analyst firms; however, no specific ratings changes or upgrades and downgrades were reported in conjunction with the announcement.


Summary of facts

  • Director Carl M. Porto bought 393 shares at $46 on March 6, 2026, totaling $18,078.
  • BWFG shares were trading at $45.05 and have returned 57% over the past year.
  • InvestingPro reports a P/E of 10.56 for BWFG and offers a Pro Research Report covering BWFG and 1,400+ U.S. equities.
  • Bankwell's Q4 2025: EPS $1.36 vs. $1.19 expected (14.29% surprise); revenue $30.32M vs. $28.06M expected.
  • The stock declined in pre-market trading despite the better-than-expected quarter; no specific analyst rating moves were disclosed.

Risks

  • Despite stronger-than-expected quarterly results, BWFG's stock fell in pre-market trading, indicating potential investor hesitation in the financials sector.
  • The lack of disclosed analyst rating changes following the earnings release introduces uncertainty about how sell-side sentiment will evolve for the banking stock.
  • Insider purchases are modest in dollar terms relative to total holdings and may have limited signaling power for market participants focused on regional banking performance.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026